End-of-day quote
Warsaw S.E.
06:00:00 2023-12-17 pm EST
|
5-day change
|
1st Jan Change
|
1.58
PLN
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
6.448
|
10.49
|
52.44
|
46.11
|
16.31
|
8.093
|
Enterprise Value (EV)
1 |
15.35
|
21.51
|
65.99
|
63.12
|
37.59
|
33.61
|
P/E ratio
|
-2.45
x
|
-3.49
x
|
-15
x
|
-13.4
x
|
-3.88
x
|
-1.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3,224
x
|
87.5
x
|
1,395
x
|
2,918
x
|
107
x
|
153
x
|
EV / Revenue
|
7,676
x
|
180
x
|
1,755
x
|
3,995
x
|
247
x
|
637
x
|
EV / EBITDA
|
-6.5
x
|
-8.32
x
|
-28.2
x
|
-18.9
x
|
-9.17
x
|
-7.03
x
|
EV / FCF
|
-12.1
x
|
-21.6
x
|
-44.1
x
|
-29.1
x
|
-13.9
x
|
-14
x
|
FCF Yield
|
-8.3%
|
-4.64%
|
-2.27%
|
-3.44%
|
-7.18%
|
-7.14%
|
Price to Book
|
-0.87
x
|
-1.01
x
|
-3.77
x
|
-2.71
x
|
-0.78
x
|
-0.31
x
|
Nbr of stocks (in thousands)
|
22,000
|
22,000
|
22,000
|
22,000
|
22,000
|
22,000
|
Reference price
2 |
0.2931
|
0.4767
|
2.384
|
2.096
|
0.7412
|
0.3679
|
Announcement Date
|
3/21/18
|
3/21/19
|
3/20/20
|
3/19/21
|
3/18/22
|
3/21/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.002
|
0.1198
|
0.0376
|
0.0158
|
0.1522
|
0.0528
|
EBITDA
1 |
-2.362
|
-2.587
|
-2.342
|
-3.333
|
-4.099
|
-4.784
|
EBIT
1 |
-2.539
|
-2.911
|
-2.65
|
-3.338
|
-4.107
|
-4.788
|
Operating Margin
|
-126,957.15%
|
-2,430.07%
|
-7,048.14%
|
-21,129.19%
|
-2,698.22%
|
-9,076.97%
|
Earnings before Tax (EBT)
1 |
-2.632
|
-3.005
|
-3.494
|
-3.434
|
-4.203
|
-4.885
|
Net income
1 |
-2.631
|
-3.001
|
-3.495
|
-3.434
|
-4.203
|
-4.885
|
Net margin
|
-131,528.95%
|
-2,504.7%
|
-9,294.43%
|
-21,734.82%
|
-2,761.49%
|
-9,260.83%
|
EPS
2 |
-0.1196
|
-0.1364
|
-0.1588
|
-0.1561
|
-0.1910
|
-0.2220
|
Free Cash Flow
1 |
-1.274
|
-0.9972
|
-1.497
|
-2.173
|
-2.698
|
-2.4
|
FCF margin
|
-63,679.15%
|
-832.37%
|
-3,981.57%
|
-13,750.67%
|
-1,772.62%
|
-4,549.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/21/18
|
3/21/19
|
3/20/20
|
3/19/21
|
3/18/22
|
3/21/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
8.9
|
11
|
13.6
|
17
|
21.3
|
25.5
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-3.769
x
|
-4.262
x
|
-5.787
x
|
-5.104
x
|
-5.192
x
|
-5.334
x
|
Free Cash Flow
1 |
-1.27
|
-1
|
-1.5
|
-2.17
|
-2.7
|
-2.4
|
ROE (net income / shareholders' equity)
|
42.8%
|
33.6%
|
28.7%
|
22.2%
|
22.1%
|
20.9%
|
ROA (Net income/ Total Assets)
|
-71.8%
|
-108%
|
-168%
|
-276%
|
-223%
|
-300%
|
Assets
1 |
3.663
|
2.79
|
2.077
|
1.246
|
1.881
|
1.627
|
Book Value Per Share
2 |
-0.3400
|
-0.4700
|
-0.6300
|
-0.7700
|
-0.9500
|
-1.170
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
0.01
|
-
|
0.01
|
0.01
|
-
|
Capex / Sales
|
-
|
5.42%
|
-
|
36.35%
|
4.26%
|
-
|
Announcement Date
|
3/21/18
|
3/21/19
|
3/20/20
|
3/19/21
|
3/18/22
|
3/21/23
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 8.75M | | -10.15% | 1.17B | | -20.42% | 125M | | +2.15% | 75.19M | | +3.39% | 58.55M | | +5.05% | 57.06M | | -2.99% | 50.8M |
Bio Medical Devices
|